Anti-Rheumatic Drugs - Senegal | Statista Market Forecast

In Senegal, the revenue in the Anti-Rheumatic Drugs market is estimated to reach US$2.27m in 2024.
It is anticipated that the revenue will experience an annual growth rate (CAGR 2024-2029) of 1.56%, leading to a market volume of US$2.45m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, with US$34.70bn in 2024.
Senegal's demand for anti-rheumatic drugs is steadily rising, driven by an aging population and an increase in rheumatic diseases.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The demand for Anti-Rheumatic Drugs in Senegal has been on the rise in recent years.

Customer preferences: Patients in Senegal prefer Anti-Rheumatic Drugs that are affordable and have fewer side effects. They also prefer drugs that are easily accessible and can be obtained without a prescription. This preference for accessibility and affordability is due to the low-income levels in the country.

Trends in the market: The market for Anti-Rheumatic Drugs in Senegal has been growing steadily due to the increasing prevalence of rheumatoid arthritis and other related diseases. The rise in the aging population has also contributed to the growth of the market. There has been an increase in the number of pharmaceutical companies that are producing Anti-Rheumatic Drugs in the country, which has led to increased competition and lower prices. The government has also been playing a role in the growth of the market by making efforts to improve healthcare access and affordability.

Local special circumstances: Senegal is a low-income country with a high burden of disease. The prevalence of rheumatoid arthritis and other related diseases is on the rise due to the aging population and changes in lifestyle. The country also has a shortage of healthcare professionals and facilities, which makes it difficult for patients to access treatment. The government has been working to address these challenges by investing in healthcare infrastructure and improving access to healthcare services.

Underlying macroeconomic factors: Senegal is a developing country with a growing economy. The government has been implementing policies to promote economic growth and reduce poverty. However, the country still faces significant challenges such as high levels of unemployment and poverty. The growth of the Anti-Rheumatic Drugs market in Senegal has been driven by the increasing demand for healthcare services and the government's efforts to improve healthcare access and affordability. The market is expected to continue growing in the coming years as the population ages and the burden of disease increases.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.